| 24323026 | Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. | J Clin Oncol | 2014 Jan 10 | Gandhi L | doi: 10.1200/JCO.2012.47.2787 |
| 26506516 | Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. | Oncotarget | 2015 Dec 8 | Qi W | doi: 10.18632/oncotarget.5659. |
| 25491778 | The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. | Breast Cancer Res Treat | 2015 Jan | Bean JR | doi: 10.1007/s10549-014-3201-6 |
| 20009539 | Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. | Cancer Biol Ther | 2009 Oct | Chang Q | - |
| 21744334 | Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer. | Folia Histochem Cytobiol | 2011 | Lauda??ski P | - |
| 25962638 | Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway. | Oncol Rep | 2015 Jun | Bai X | doi: 10.3892/or.2015.3922 |
| 25478811 | mTOR and PDGF pathway blockade inhibits liver metastasis of colorectal cancer by modulating the tumor microenvironment. | Am J Pathol | 2015 Feb | Yuge R | doi: 10.1016/j.ajpath.2014.10.014 |
| 20030877 | Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy. | Breast Cancer Res | 2009 | Di Cosimo S | doi: 10.1186/bcr2444 |
| 25046358 | A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling. | Cancer Biol Ther | 2014 Oct | Song Y | doi: 10.4161/cbt.29925 |
| 22907434 | ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. | Oncogene | 2013 Jul 11 | Du W | doi: 10.1038/onc.2012.359 |
| 20226010 | Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. | Mol Cancer | 2010 Mar 12 | Roulin D | doi: 10.1186/1476-4598-9-57. |
| 26523512 | Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. | Biochem Biophys Res Commun | 2015 Dec 25 | Zhang D | doi: 10.1016/j.bbrc.2015.10.129 |
| 28377226 | Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling. | Biochem Biophys Res Commun | 2017 May 13 | Huang X | doi: 10.1016/j.bbrc.2017.03.168 |
| 27153561 | Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors. | Oncotarget | 2016 Jun 14 | Faes S | doi: 10.18632/oncotarget.9134. |
| 29233126 | Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. | BMC Cancer | 2017 Dec 12 | Cao GD | doi: 10.1186/s12885-017-3851-y. |
| 27507059 | Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC. | Oncotarget | 2016 Sep 13 | Piao J | doi: 10.18632/oncotarget.11109. |
| 21266827 | Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer. | Pathobiology | 2010 | Koo JS | doi: 10.1159/000320936 |
| 24469052 | p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. | Oncogene | 2015 Jan 29 | Akeno N | doi: 10.1038/onc.2013.589 |
| 27034171 | Rheb may complex with RASSF1A to coordinate Hippo and TOR signaling. | Oncotarget | 2016 Jun 7 | Nelson N | doi: 10.18632/oncotarget.8447. |
| 25110431 | Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. | World J Gastroenterol | 2014 Aug 7 | Spampatti M | doi: 10.3748/wjg.v20.i29.10038. |
| 26418749 | Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression. | Oncotarget | 2015 Oct 20 | Wu M | doi: 10.18632/oncotarget.5018. |
| 25341684 | SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation. | J Pharmacol Sci | 2014 | Wang J | - |
| 21383697 | MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. | Oncogene | 2011 Aug 11 | Oneyama C | doi: 10.1038/onc.2011.63 |
| 16929481 | Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation. | Mol Carcinog | 2006 Dec | Ahlemann M | - |
| 26261591 | Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization. | Int J Clin Exp Pathol | 2015 Jun 1 | Melling N | - |
| 19090006 | Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. | Cancer | 2009 Jan 1 | Dobashi Y | doi: 10.1002/cncr.23996. |
| 21859551 | [Advances of LKB1-AMPK-mTOR Signaling Pathway in Tumor]. | Zhongguo Fei Ai Za Zhi | 2011 Aug | Zhang X | doi: 10.3779/j.issn.1009-3419.2011.08.09. |
| 26722465 | Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma. | Int J Clin Exp Pathol | 2015 Oct 1 | Chuang WY | - |
| 27226604 | Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. | J Biol Chem | 2016 Jul 1 | Holmes B | doi: 10.1074/jbc.M116.726927 |
| 27012089 | [REGULATION OF THE mTOR SIGNALING PATHWAY IN MACROPHAGES IN VARIOUS PATHOLOGIES]. | Tsitologiia | 2015 | Zubova SG | - |
| 25931349 | Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines. | Adv Clin Exp Med | 2015 Mar-Apr | Szyma??ska J | doi: 10.17219/acem/32934. |
| 25862847 | Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. | Anticancer Res | 2015 Apr | Aderhold C | - |
| 19098000 | The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. | J Biol Chem | 2009 Feb 20 | Harada H | doi: 10.1074/jbc.M806653200 |
| 18926585 | Role of TSC-mTOR pathway in diabetic nephropathy. | Diabetes Res Clin Pract | 2008 Nov 13 | Inoki K | doi: 10.1016/j.diabres.2008.09.028 |
| 25667121 | The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway. | Cancer Lett | 2015 Apr 28 | Zhou W | doi: 10.1016/j.canlet.2015.02.004 |
| 25778319 | Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression. | J BUON | 2015 Jan-Feb | Zhang CZ | - |
| 26255626 | Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. | Oncotarget | 2015 Jul 20 | Ghosh AP | - |
| 19956179 | Common corruption of the mTOR signaling network in human tumors. | Oncogene | 2008 Dec | Menon S | doi: 10.1038/onc.2009.352. |
| 22871496 | Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth. | Carcinogenesis | 2012 Nov | Rico C | doi: 10.1093/carcin/bgs263 |
| 16912159 | Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. | Cancer Res | 2006 Aug 15 | Wang MY | - |
| 28064317 | [B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors]. | Mol Biol (Mosk) | 2016 Nov-Dec | Zeng S | doi: 10.7868/S0026898416060240. |
| 19147764 | Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. | Clin Cancer Res | 2009 Jan 15 | Murphy JD | doi: 10.1158/1078-0432.CCR-08-1019. |
| 23103253 | HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. | Mol Cell | 2012 Dec 14 | Elorza A | doi: 10.1016/j.molcel.2012.09.017 |
| 26170313 | Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. | Proc Natl Acad Sci U S A | 2015 Jul 28 | Masui K | doi: 10.1073/pnas.1511759112 |
| 25807077 | Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect. | PLoS One | 2015 Mar 25 | Lu CL | doi: 10.1371/journal.pone.0121046 |
| 22944293 | Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma. | Hum Pathol | 2013 Feb | Kim SH | doi: 10.1016/j.humpath.2012.05.011 |
| 17148679 | Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. | Am J Pathol | 2006 Dec | Peponi E | - |
| 22287548 | Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. | Cancer Res | 2012 Mar 15 | Chen W | doi: 10.1158/0008-5472.CAN-11-2684 |
| 21837670 | The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. | Cancer | 2012 Mar 15 | Setsu N | doi: 10.1002/cncr.26448 |
| 23963361 | Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-??B and mTOR dual-targeting approach. | Mol Cancer Ther | 2013 Oct | Chaturvedi NK | doi: 10.1158/1535-7163.MCT-13-0239 |
| 26208432 | mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. | Cancer Lett | 2015 Oct 10 | Karthik GM | doi: 10.1016/j.canlet.2015.07.017 |
| 20668229 | The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. | Blood | 2010 Nov 18 | Green AS | doi: 10.1182/blood-2010-02-269837 |
| 23878245 | Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. | Proc Natl Acad Sci U S A | 2013 Aug 6 | Tripathi DN | doi: 10.1073/pnas.1307736110 |
| 18650380 | ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. | Proc Natl Acad Sci U S A | 2008 Jul 29 | Schewe DM | doi: 10.1073/pnas.0800939105 |
| 20048174 | Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. | J Clin Oncol | 2010 Feb 10 | Wagner AJ | doi: 10.1200/JCO.2009.25.2981 |
| 25854175 | MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway. | Tumour Biol | 2015 Sep | Shen L | doi: 10.1007/s13277-015-3409-z |
| 26993162 | FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell. | Biochem Biophys Res Commun | 2016 May 20 | Chen Y | doi: 10.1016/j.bbrc.2016.03.017 |
| 28159681 | The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). | Cancer Lett | 2017 Apr 28 | Gazi M | doi: 10.1016/j.canlet.2017.01.035 |
| 27693556 | Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. | Cancer Lett | 2016 Dec 28 | Muqbil I | doi: 10.1016/j.canlet.2016.09.016 |
| 28419191 | PPAR?? promotes tumor progression via activation of Glut1 and SLC1-A5 transcription. | Carcinogenesis | 2017 Jul 1 | Zhang W | doi: 10.1093/carcin/bgx035. |
| 27835987 | Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis. | BMC Cancer | 2016 Nov 11 | Li S | - |
| 28582508 | Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium. | Carcinogenesis | 2017 Aug 1 | Wang S | doi: 10.1093/carcin/bgx055. |
| 28745319 | The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer. | Oncogene | 2017 Nov 16 | D'Abronzo LS | doi: 10.1038/onc.2017.233 |
| 27147575 | Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. | Oncotarget | 2016 May 31 | Dong L | doi: 10.18632/oncotarget.9061. |
| 27283897 | Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. | Oncotarget | 2016 Jul 12 | Yang Z | doi: 10.18632/oncotarget.9873. |
| 27174915 | IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. | Oncotarget | 2016 Aug 16 | Folgiero V | doi: 10.18632/oncotarget.9284. |
| 27285754 | PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. | Oncotarget | 2016 Jul 5 | Matsumoto CS | doi: 10.18632/oncotarget.9877. |
| 28002802 | Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. | Oncotarget | 2017 Jan 31 | Fourneaux B | doi: 10.18632/oncotarget.13987. |
| 28498460 | MCM7 amplification and overexpression promote cell proliferation, colony formation and migration in esophageal squamous cell carcinoma by activating the AKT1/mTOR signaling pathway. | Oncol Rep | 2017 Jun | Qiu YT | doi: 10.3892/or.2017.5614 |
| 28440461 | The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required. | Int J Oncol | 2017 Jun | Zhao K | doi: 10.3892/ijo.2017.3973 |
| 28052030 | The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo. | Oncotarget | 2017 Jan 31 | Fujihara S | doi: 10.18632/oncotarget.14345. |
| 29491094 | mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study. | Anticancer Res | 2018 Mar | Kawasaki G | - |
| 28468774 | Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. | Mol Cancer Ther | 2017 Jul | Gordon MA | doi: 10.1158/1535-7163.MCT-17-0111 |
| 28007777 | Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. | Clin Cancer Res | 2017 Jun 15 | Truillet C | doi: 10.1158/1078-0432.CCR-16-2448 |
| 28624790 | Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. | Oncotarget | 2017 Jul 18 | Cheng H | doi: 10.18632/oncotarget.18207. |
| 28791373 | Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway. | Oncol Rep | 2017 Oct | Cheng DD | doi: 10.3892/or.2017.5890 |
| 29048631 | Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells. | Oncol Rep | 2017 Nov | Kou B | doi: 10.3892/or.2017.5988 |
| 29448085 | Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. | Neoplasia | 2018 Mar | Matthew EM | doi: 10.1016/j.neo.2018.01.004 |
| 30488209 | Association of Target Therapy Gene Expression with Metastasizing of Clear-Cell Renal Cell Carcinoma. | Bull Exp Biol Med | 2018 Dec | Apanovich NV | doi: 10.1007/s10517-018-4327-z |
| 29403037 | The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168. | Nat Cell Biol | 2018 Mar | Xie X | doi: 10.1038/s41556-017-0033-8 |
| 18831768 | TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells. | BMC Cancer | 2008 Oct 3 | Hietakangas V | doi: 10.1186/1471-2407-8-282. |
| 20081105 | A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. | Mol Endocrinol | 2010 Feb | Nagaraja AK | doi: 10.1210/me.2009-0295 |
| 23773481 | Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers. | Hum Pathol | 2013 Oct | Alqurashi N | doi: 10.1016/j.humpath.2013.03.014 |
| 26097572 | Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer. | Int J Clin Exp Pathol | 2015 Apr 1 | Wu S | - |
| 24853425 | SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. | Cell Death Dis | 2014 May 22 | Yuan LJ | doi: 10.1038/cddis.2014.222. |
| 25843797 | DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. | Biochem Biophys Res Commun | 2015 May 15 | Obara A | doi: 10.1016/j.bbrc.2015.03.148 |
| 25531318 | LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. | Oncogene | 2015 Sep 24 | Mura M | doi: 10.1038/onc.2014.428 |
| 23246968 | The evolution of the TOR pathway and its role in cancer. | Oncogene | 2013 Aug 22 | Beauchamp EM | doi: 10.1038/onc.2012.567 |
| 27315344 | MicroRNA-224 aggrevates tumor growth and progression by targeting mTOR in gastric cancer. | Int J Oncol | 2016 Sep | Zhang Y | doi: 10.3892/ijo.2016.3581 |
| 27109477 | FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway. | Biochem Biophys Res Commun | 2016 May 27 | Huang X | doi: 10.1016/j.bbrc.2016.04.106 |
| 28235484 | Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function. | Biochem Biophys Res Commun | 2017 Apr 29 | Zhang L | doi: 10.1016/j.bbrc.2017.02.101 |
| 28698135 | MREG suppresses thyroid cancer cell invasion and proliferation by inhibiting Akt-mTOR signaling. | Biochem Biophys Res Commun | 2017 Sep 9 | Meng X | doi: 10.1016/j.bbrc.2017.07.044 |
| 27991928 | Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. | Oncogene | 2017 May 11 | Mateo F | doi: 10.1038/onc.2016.427 |
| 29307829 | Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases. | Biochem Biophys Res Commun | 2018 Jan 29 | Li Z | doi: 10.1016/j.bbrc.2018.01.016 |
| 27533457 | Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population. | Oncotarget | 2016 Sep 6 | Zhao Y | doi: 10.18632/oncotarget.11272. |
| 29978609 | Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells. | Yonsei Med J | 2018 Aug | Ahn K | doi: 10.3349/ymj.2018.59.6.727. |
| 29749504 | LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells. | Oncol Rep | 2018 Jul | Wei Y | doi: 10.3892/or.2018.6432 |
| 30061533 | mTOR and Tumor Cachexia. | Int J Mol Sci | 2018 Jul 30 | Duval AP | doi: 10.3390/ijms19082225. |
| 30171261 | mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. | Oncogene | 2019 Jan | Liang SQ | doi: 10.1038/s41388-018-0479-6 |
| 26287940 | Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population. | Pharmacogenet Genomics | 2015 Nov | Wang MY | doi: 10.1097/FPC.0000000000000163. |
| 26201060 | The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer. | Toxicology | 2015 Sep 1 | Leisching GR | doi: 10.1016/j.tox.2015.07.010 |
| 26311737 | Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells. | Oncotarget | 2015 Oct 6 | Tsai JP | doi: 10.18632/oncotarget.4767. |
| 23530221 | Hypoxia induces a phase transition within a kinase signaling network in cancer cells. | Proc Natl Acad Sci U S A | 2013 Apr 9 | Wei W | doi: 10.1073/pnas.1303060110 |
| 26319900 | Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells. | Cancer Lett | 2015 Dec 1 | Altman MK | doi: 10.1016/j.canlet.2015.08.012 |
| 24556942 | Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression. | Urol Int | 2014 | Ko YH | doi: 10.1159/000356262 |
| 26427150 | Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells. | Clin Lab | 2015 | Ji Y | - |
| 25421824 | Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling. | Int J Oncol | 2015 Feb | Hsieh CJ | doi: 10.3892/ijo.2014.2769 |
| 19739122 | Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. | Int J Cancer | 2010 Jun 15 | An JY | doi: 10.1002/ijc.24872. |
| 20204306 | RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. | Oncol Rep | 2010 Apr | Wang ZG | - |
| 20354165 | Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. | Cancer Prev Res (Phila) | 2010 Apr | Lin J | doi: 10.1158/1940-6207.CAPR-09-0263 |
| 26238185 | MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. | Oncotarget | 2015 Sep 22 | Xu S | doi: 10.18632/oncotarget.4762. |
| 22127531 | mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry. | Surg Today | 2012 May | Wang L | doi: 10.1007/s00595-011-0028-1 |
| 25632222 | Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. | Drug Des Devel Ther | 2015 Jan 17 | Wang F | doi: 10.2147/DDDT.S73689 |
| 19553815 | Promising molecular targets in ovarian cancer. | Curr Opin Oncol | 2009 Sep | Blagden S | doi: 10.1097/CCO.0b013e32832eab1f. |
| 25854169 | Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway. | Tumour Biol | 2015 Aug | Han B | doi: 10.1007/s13277-015-3315-4 |
| 23832540 | Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. | Tumour Biol | 2013 Dec | Yothaisong S | doi: 10.1007/s13277-013-0945-2 |
| 27090655 | Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. | BMC Syst Biol | 2016 Apr 18 | Andorfer P | doi: 10.1186/s12918-016-0278-z. |
| 21276607 | Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. | Gynecol Oncol | 2011 Apr | No JH | doi: 10.1016/j.ygyno.2010.12.364 |
| 19164214 | Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. | J Clin Oncol | 2009 Feb 20 | Hildebrandt MA | doi: 10.1200/JCO.2008.17.6297 |
| 20019839 | CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. | Neoplasia | 2009 Dec | Roca H | - |
| 21177869 | mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. | J Biol Chem | 2011 Feb 25 | Liu J | doi: 10.1074/jbc.M110.183087 |
| 18413763 | A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. | Cancer Res | 2008 Apr 15 | Shor B | doi: 10.1158/0008-5472.CAN-07-6487. |
| 20153512 | Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. | Hum Pathol | 2010 Jun | Bunkholt Elstrand M | doi: 10.1016/j.humpath.2009.09.017 |
| 20093977 | Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. | J Thorac Oncol | 2010 Mar | Dhillon T | doi: 10.1097/JTO.0b013e3181ce6604. |
| 23423739 | Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. | Mol Carcinog | 2013 Nov | He J | doi: 10.1002/mc.22013 |
| 25460505 | DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1. | Oncotarget | 2015 Jan 1 | Selvarajah J | - |
| 25632225 | Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. | Drug Des Devel Ther | 2015 Jan 17 | Wang F | doi: 10.2147/DDDT.S75221 |
| 19897009 | The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. | Mol Cell Endocrinol | 2010 May 28 | Saji M | doi: 10.1016/j.mce.2009.10.016 |
| 26577839 | Genetic variants in the mTOR pathway and breast cancer risk in African American women. | Carcinogenesis | 2016 Jan | Cheng TD | doi: 10.1093/carcin/bgv160 |
| 15802268 | Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. | J Biol Chem | 2005 Jun 10 | Phillips RJ | - |
| 19949304 | The role of mTOR in bladder cancer. | Cancer Biol Ther | 2009 Dec | Gust KM | - |
| 23940798 | Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population. | PLoS One | 2013 Aug 5 | Li Q | doi: 10.1371/journal.pone.0071968 |
| 25051360 | Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. | Oncotarget | 2014 Jul 15 | Davis NM | - |
| 27220494 | MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop and the Akt-mTOR signaling pathway. | Tumour Biol | 2016 Sep | Song L | - |
| 25108739 | Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. | Breast Cancer Res Treat | 2014 Sep | Pande M | doi: 10.1007/s10549-014-3081-9 |
| 25043667 | Expression of phosphorylated-mTOR during the development of prostate cancer. | Prostate | 2014 Sep | Sutherland SI | doi: 10.1002/pros.22840 |
| 18702307 | [Role of PTEN protein in multidrug resistance of prostate cancer cells]. | Mol Biol (Mosk) | 2008 May-Jun | Sherbakova EA | - |
| 23886172 | Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer. | Asian Pac J Cancer Prev | 2013 | Zhang Y | - |
| 23623586 | Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. | Hum Pathol | 2013 Sep | Fahmy M | doi: 10.1016/j.humpath.2012.11.026 |
| 17409838 | Targeting mTOR signaling for lung cancer therapy. | J Thorac Oncol | 2006 Feb | Sun SY | - |
| 12813467 | Phospholipase D confers rapamycin resistance in human breast cancer cells. | Oncogene | 2003 Jun 19 | Chen Y | - |
| 18570873 | mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. | Mol Cell | 2008 Jun 20 | Hong F | doi: 10.1016/j.molcel.2008.04.027. |
| 23322780 | Mutations in critical domains confer the human mTOR gene strong tumorigenicity. | J Biol Chem | 2013 Mar 1 | Murugan AK | doi: 10.1074/jbc.M112.399485 |
| 27055253 | Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. | PLoS One | 2016 Apr 7 | Cardnell RJ | doi: 10.1371/journal.pone.0152584 |
| 20727662 | Clinical significance of pmTOR expression in endometrioid endometrial carcinoma. | Eur J Obstet Gynecol Reprod Biol | 2010 Dec | Choi CH | doi: 10.1016/j.ejogrb.2010.07.038 |
| 17616691 | AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. | Cancer Res | 2007 Jul 1 | Liu LZ | - |
| 18622747 | Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines. | Sci China C Life Sci | 2008 Jul | Sun D | doi: 10.1007/s11427-008-0080-2 |
| 26158266 | Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells. | PLoS One | 2015 Jul 9 | Woo YM | doi: 10.1371/journal.pone.0132285 |
| 22367541 | The translational landscape of mTOR signalling steers cancer initiation and metastasis. | Nature | 2012 Feb 22 | Hsieh AC | doi: 10.1038/nature10912. |
| 20805015 | Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. | Cancer Lett | 2010 Dec 18 | Toschi A | doi: 10.1016/j.canlet.2010.08.006. |
| 20630061 | Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. | BMC Cancer | 2010 Jul 14 | Javle MM | doi: 10.1186/1471-2407-10-368. |
| 25735853 | A liaison between mTOR signaling, ribosome biogenesis and cancer. | Biochim Biophys Acta | 2015 Jul | Gentilella A | doi: 10.1016/j.bbagrm.2015.02.005 |
| 26639561 | BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. | Sci Rep | 2015 Dec 7 | Karachaliou N | doi: 10.1038/srep17499. |
| 19624311 | GOLPH3 links the Golgi network to mTOR signaling and human cancer. | Pigment Cell Melanoma Res | 2009 Aug | Abraham RT | doi: 10.1111/j.1755-148X.2009.00596.x. |
| 22684558 | Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation. | J Huazhong Univ Sci Technolog Med Sci | 2012 Jun | Ma X | doi: 10.1007/s11596-012-0062-2 |
| 25659153 | Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway. | PLoS One | 2015 Feb 6 | Li G | doi: 10.1371/journal.pone.0117440 |
| 19020722 | Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. | Oncol Rep | 2008 Dec | Noske A | - |
| 21372221 | Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. | Clin Cancer Res | 2011 Apr 15 | Santiskulvong C | doi: 10.1158/1078-0432.CCR-10-2289 |
| 24334141 | mTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells. | Biochim Biophys Acta | 2014 Jan | Vikhreva PN | doi: 10.1016/j.bbagrm.2013.12.001 |
| 26823699 | Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling. | Int J Clin Exp Pathol | 2015 Nov 1 | Mu DW | - |
| 22983984 | Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. | Carcinogenesis | 2012 Dec | Iwaya T | doi: 10.1093/carcin/bgs288 |
| 24695460 | Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth. | Int J Clin Exp Pathol | 2014 Feb 15 | Du YF | - |
| 26160839 | Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism. | Oncotarget | 2015 Sep 15 | Chen GQ | - |
| 22029423 | Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. | Radiat Oncol | 2011 Oct 26 | Rashid A | doi: 10.1186/1748-717X-6-144. |
| 24571487 | Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. | Respir Res | 2014 Feb 26 | Kim EY | doi: 10.1186/1465-9921-15-26. |
| 24816861 | Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis. | PLoS One | 2014 May 9 | Shao J | doi: 10.1371/journal.pone.0097085 |
| 23841076 | The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53. | Biomed Res Int | 2013 | Shin S | doi: 10.1155/2013/568671 |
| 17693255 | IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. | Cell | 2007 Aug 10 | Lee DF | - |
| 19223902 | Relation between outcomes and localisation of p-mTOR expression in gastric cancer. | Br J Cancer | 2009 Mar 10 | Murayama T | doi: 10.1038/sj.bjc.6604915 |
| 18776922 | Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. | Oncogene | 2008 Nov 27 | Wang Y | doi: 10.1038/onc.2008.318 |
| 20479250 | PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. | Proc Natl Acad Sci U S A | 2010 Jun 1 | Loi S | doi: 10.1073/pnas.0907011107 |
| 25600244 | Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer. | Clin Breast Cancer | 2015 Jun | Yanai A | doi: 10.1016/j.clbc.2014.12.002 |
| 21277936 | Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. | Exp Hematol | 2011 Apr | Batista A | doi: 10.1016/j.exphem.2011.01.005 |
| 24624456 | PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. | Hepatogastroenterology | 2013 Oct | Zhang Y | - |
| 22471665 | Targeting PI3 kinase/AKT/mTOR signaling in cancer. | Crit Rev Oncog | 2012 | Sheppard K | - |
| 20061787 | Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. | Cancer Biol Ther | 2009 Dec | Mansure JJ | - |
| 25029414 | Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. | J Clin Endocrinol Metab | 2014 Oct | Malaguarnera R | doi: 10.1210/jc.2013-3976 |
| 26012635 | HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive. | Sci Signal | 2015 May 26 | Singh N | doi: 10.1126/scisignal.aaa6922. |
| 26267321 | The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. | Oncotarget | 2015 Sep 22 | Bai H | doi: 10.18632/oncotarget.4550. |
| 26652716 | MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression. | Diagn Pathol | 2015 Dec 12 | Bornschein J | doi: 10.1186/s13000-015-0449-z. |
| 26339598 | Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition. | Biomed Res Int | 2015 | Kim N | doi: 10.1155/2015/239764 |
| 23555892 | A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. | PLoS One | 2013 | Xu M | doi: 10.1371/journal.pone.0060080 |
| 26235873 | Inactivated Sendai virus induces apoptosis and autophagy via the PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer cells. | Biochem Biophys Res Commun | 2015 Sep 11 | Zhang Q | doi: 10.1016/j.bbrc.2015.07.130 |
| 23933173 | mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo. | Cancer Lett | 2013 Dec 1 | Yang C | doi: 10.1016/j.canlet.2013.08.004 |
| 21325052 | Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. | Proc Natl Acad Sci U S A | 2011 Mar 8 | Sun Q | doi: 10.1073/pnas.1014769108 |
| 24637915 | MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. | PLoS One | 2014 Mar 17 | Hu Y | doi: 10.1371/journal.pone.0092099 |
| 15028555 | G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. | Am J Physiol Cell Physiol | 2004 Aug | Gao N | - |
| 26432419 | Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer. | Cancer Sci | 2015 Dec | Yamaguchi H | doi: 10.1111/cas.12828 |
| 21412012 | Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer. | Oncology | 2010 | Kim JG | doi: 10.1159/000320761 |
| 26744318 | MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. | Oncotarget | 2016 Feb 2 | Zhang B | doi: 10.18632/oncotarget.6790. |
| 24011934 | Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. | Eur J Cancer | 2013 Dec | Sheppard KE | doi: 10.1016/j.ejca.2013.08.007 |
| 25816324 | Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. | PLoS One | 2015 Mar 27 | Deng L | doi: 10.1371/journal.pone.0120511 |
| 26585486 | Activation of mTORC1 under nutrient starvation conditions increases cellular radiosensitivity in human liver cancer cell lines, HepG2 and HuH6. | Biochem Biophys Res Commun | 2015 Dec 25 | Murata Y | doi: 10.1016/j.bbrc.2015.11.016 |
| 24027431 | TBK1 regulates prostate cancer dormancy through mTOR inhibition. | Neoplasia | 2013 Sep | Kim JK | - |
| 18395956 | Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. | Eur J Obstet Gynecol Reprod Biol | 2008 Aug | Zhang XY | doi: 10.1016/j.ejogrb.2007.12.021 |
| 25918246 | mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. | Mol Cell Biol | 2015 Jul | Koo J | doi: 10.1128/MCB.01525-14 |
| 20811725 | 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. | Int J Oncol | 2010 Oct | Li CM | - |
| 26935715 | Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-??B activation. | Naunyn Schmiedebergs Arch Pharmacol | 2016 Jun | Bai C | doi: 10.1007/s00210-016-1217-7 |
| 23178462 | Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. | Acta Pharmacol Sin | 2013 Feb | Dong LX | doi: 10.1038/aps.2012.143 |
| 20459645 | Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. | Mol Cancer | 2010 May 7 | Ahmed M | doi: 10.1186/1476-4598-9-101. |
| 19020730 | TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. | Oncol Rep | 2008 Dec | Wang ZG | - |
| 24630930 | Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway. | Biochem Pharmacol | 2014 May 15 | Glorieux C | doi: 10.1016/j.bcp.2014.02.025 |
| 25749387 | The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer. | Oncotarget | 2015 Mar 30 | Zheng G | - |
| 18612547 | Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. | Thromb Haemost | 2008 Jul | Jiang X | doi: 10.1160/TH07-12-0722. |
| 21339740 | Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. | Oncogene | 2011 Jun 30 | Kim EK | doi: 10.1038/onc.2011.22 |
| 26780727 | Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway. | Biochem Biophys Res Commun | 2016 Feb 5 | Liu Y | doi: 10.1016/j.bbrc.2016.01.046 |
| 22457328 | . | Sci Signal | 2012 Mar 27 | Fingar DC | doi: 10.1126/scisignal.2003026. |
| 22349822 | Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis. | Oncogene | 2013 Jan 10 | Wen ZH | doi: 10.1038/onc.2012.47 |
| 22452883 | Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin. | Mol Cancer Res | 2012 Jun | Wahdan-Alaswad RS | doi: 10.1158/1541-7786.MCR-11-0615 |
| 21886838 | Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. | PLoS One | 2011 | Basu A | doi: 10.1371/journal.pone.0023919 |
| 23991038 | Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. | PLoS One | 2013 Aug 26 | Zhang X | doi: 10.1371/journal.pone.0072053 |
| 17911267 | Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. | Proc Natl Acad Sci U S A | 2007 Oct 9 | Zhou J | - |
| 18848473 | The TSC-mTOR signaling pathway regulates the innate inflammatory response. | Immunity | 2008 Oct 17 | Weichhart T | doi: 10.1016/j.immuni.2008.08.012 |
| 23297825 | Targeting the mTOR pathway in tumor malignancy. | Curr Cancer Drug Targets | 2013 Mar | Cheng H | - |
| 16341243 | Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. | Nat Med | 2006 Jan | Thomas GV | - |
| 21035497 | Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. | Adv Enzyme Regul | 2011 | Jhanwar-Uniyal M | doi: 10.1016/j.advenzreg.2010.09.017 |
| 24631838 | A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. | Cancer Discov | 2014 May | Grabiner BC | doi: 10.1158/2159-8290.CD-13-0929 |
| 25128827 | PGE2-induced colon cancer growth is mediated by mTORC1. | Biochem Biophys Res Commun | 2014 Sep 5 | Dufour M | doi: 10.1016/j.bbrc.2014.08.032 |
| 19875696 | Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. | Carcinogenesis | 2009 Dec | Chen M | doi: 10.1093/carcin/bgp258. |
| 26427711 | Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression. | In Vitro Cell Dev Biol Anim | 2016 Jan | Fujii T | doi: 10.1007/s11626-015-9944-5 |
| 20145209 | ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. | Sci Signal | 2010 Feb 9 | Kuo HP | doi: 10.1126/scisignal.2000590. |
| 21046231 | The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. | Breast Cancer Res Treat | 2011 Sep | Br??nner-Kubath C | doi: 10.1007/s10549-010-1232-1 |
| 26284586 | mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. | Oncotarget | 2015 Nov 24 | Hanly EK | doi: 10.18632/oncotarget.4052. |
| 19223493 | Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. | Clin Cancer Res | 2009 Mar 1 | Yu G | doi: 10.1158/1078-0432.CCR-08-2138 |
| 22815832 | Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. | PLoS One | 2012 | Chen J | doi: 10.1371/journal.pone.0040817 |
| 20929525 | Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. | BMC Cancer | 2010 Oct 7 | Xu DZ | doi: 10.1186/1471-2407-10-536. |
| 16786123 | Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. | Oncol Rep | 2006 Jul | Faried LS | - |
| 22340595 | Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. | Cancer Cell | 2012 Feb 14 | Muranen T | doi: 10.1016/j.ccr.2011.12.024. |
| 17631500 | Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. | J Biol Chem | 2007 Sep 7 | Yoon S | - |
| 26617795 | TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway. | Int J Clin Exp Pathol | 2015 Sep 1 | Xu X | - |
| 27796683 | Akt/AMPK/mTOR pathway was involved in the autophagy induced by vitamin E succinate in human gastric cancer SGC-7901 cells. | Mol Cell Biochem | 2017 Jan | Yu Y | doi: 10.1007/s11010-016-2853-4 |
| 26753650 | Expression of mTOR and its inhibitory effect on cell proliferation and apoptosis of breast cancer cells. | J Biol Regul Homeost Agents | 2015 Oct-Dec | Cheng XF | - |
| 19553991 | GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. | Nature | 2009 Jun 25 | Scott KL | doi: 10.1038/nature08109. |
| 24508774 | Targeting bone metastatic cancer: Role of the mTOR pathway. | Biochim Biophys Acta | 2014 Apr | Bertoldo F | doi: 10.1016/j.bbcan.2014.01.009 |
| 16652388 | Expression of mTOR signaling pathway markers in prostate cancer progression. | Prostate | 2006 Aug 1 | Kremer CL | - |
| 22399812 | TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. | J Cell Sci | 2012 Mar 1 | Lamouille S | doi: 10.1242/jcs.095299 |
| 18519641 | Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. | Genes Dev | 2008 Jun 1 | Dan HC | doi: 10.1101/gad.1662308. |
| 17545512 | The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. | Clin Cancer Res | 2007 Jun 1 | Abraham RT | - |
| 26499488 | Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells. | Int J Mol Med | 2015 Dec | Wang KF | doi: 10.3892/ijmm.2015.2378 |
| 15580312 | Alternative phospholipase D/mTOR survival signal in human breast cancer cells. | Oncogene | 2005 Jan 20 | Chen Y | - |
| 27572296 | RLIP76 increases apoptosis through Akt/mTOR signaling pathway in gastric cancer. | Oncol Rep | 2016 Oct | Wang W | doi: 10.3892/or.2016.5043 |
| 25729885 | Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking. | Cancer Biol Ther | 2015 | Bao X | doi: 10.1080/15384047.2015.1019184 |
| 20190810 | Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. | Oncogene | 2010 May 6 | Sato T | doi: 10.1038/onc.2010.28 |
| 12242281 | Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. | Mol Cell Biol | 2002 Oct | Hudson CC | - |
| 23828865 | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. | Endocr Relat Cancer | 2013 Aug 21 | Gild ML | doi: 10.1530/ERC-13-0085 |
| 23886294 | miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. | Mol Cancer | 2013 Jul 25 | Wei F | doi: 10.1186/1476-4598-12-81. |
| 24991762 | CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. | Cell Death Dis | 2014 Jul 3 | Ieran?? C | doi: 10.1038/cddis.2014.269. |
| 21373201 | Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). | PLoS One | 2011 Feb 23 | Campa D | doi: 10.1371/journal.pone.0016914. |
| 20811722 | Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. | Int J Oncol | 2010 Oct | Nagata Y | - |
| 18652687 | Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. | BMC Genomics | 2008 Jul 24 | Heinonen H | doi: 10.1186/1471-2164-9-348. |
| 21170086 | Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction. | Oncogene | 2011 Mar 31 | Colombi M | doi: 10.1038/onc.2010.539 |
| 26367112 | MiR-634 decreases cell proliferation and induces apoptosis by targeting mTOR signaling pathway in cervical cancer cells. | Artif Cells Nanomed Biotechnol | 2016 Nov | Cong J | doi: 10.3109/21691401.2015.1080171 |
| 24668416 | miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway. | Med Oncol | 2014 May | Wang L | doi: 10.1007/s12032-014-0934-3 |
| 22685542 | microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. | PLoS One | 2012 | Dey N | doi: 10.1371/journal.pone.0037366 |
| 17616684 | Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. | Cancer Res | 2007 Jul 1 | Dan HC | - |
| 18787170 | FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. | Science | 2008 Sep 12 | Mao JH | doi: 10.1126/science.1162981. |
| 22952422 | Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. | Neoplasia | 2012 Aug | Weekes CD | - |
| 27959445 | Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells. | Oncol Rep | 2017 Feb | Kim MH | doi: 10.3892/or.2016.5296 |
| 28408137 | 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. | Toxicol Appl Pharmacol | 2017 Jun 15 | Liu M | doi: 10.1016/j.taap.2017.04.003 |
| 27211906 | Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro. | Int J Oncol | 2016 Jul | Rogers-Broadway KR | doi: 10.3892/ijo.2016.3531 |
| 27996156 | α-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer. | Mol Carcinog | 2017 May | Zhan P | doi: 10.1002/mc.22603 |
| 27301639 | PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy. | Biochem Biophys Res Commun | 2016 Aug 19 | Park JH | doi: 10.1016/j.bbrc.2016.06.057 |
| 28639903 | Targeting the mTOR pathway in breast cancer. | Tumour Biol | 2017 Jun | Liu J | doi: 10.1177/1010428317710825. |
| 28005970 | Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer. | PLoS One | 2016 Dec 22 | Cao GD | doi: 10.1371/journal.pone.0168085 |
| 27746162 | Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. | Cancer Lett | 2017 Jan 1 | Mimoto R | doi: 10.1016/j.canlet.2016.10.015 |
| 27385486 | Mutant p53 and mTOR/PKM2 regulation in cancer cells. | IUBMB Life | 2016 Sep | Dando I | doi: 10.1002/iub.1534 |
| 26876207 | Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. | Oncogene | 2016 Sep 1 | Zhou J | doi: 10.1038/onc.2016.4 |
| 28574664 | Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma. | Cancer Sci | 2017 Aug | Wang H | doi: 10.1111/cas.13289 |
| 28870807 | A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling. | Biochem Biophys Res Commun | 2017 Nov 4 | Pei Z | doi: 10.1016/j.bbrc.2017.08.170 |
| 28716898 | TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer. | Cancer Res | 2017 Sep 15 | Cooper JM | doi: 10.1158/0008-5472.CAN-17-0829 |
| 28923857 | MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway. | Cancer Res | 2017 Nov 1 | Yu T | doi: 10.1158/0008-5472.CAN-17-0671 |
| 27036037 | Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium. | Oncotarget | 2016 Apr 12 | Bajwa P | doi: 10.18632/oncotarget.8468. |
| 26895472 | mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. | Oncotarget | 2016 May 10 | Rotundo MS | doi: 10.18632/oncotarget.7446. |
| 29103666 | Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. | Eur J Cancer | 2017 Dec | Le Rhun E | doi: 10.1016/j.ejca.2017.10.006 |
| 27009856 | mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells. | Oncotarget | 2016 May 3 | Wang CI | doi: 10.18632/oncotarget.8170. |
| 27150059 | Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. | Oncotarget | 2016 May 24 | Kan JY | doi: 10.18632/oncotarget.9140. |
| 27096957 | mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. | Oncotarget | 2016 May 31 | Stelloo S | doi: 10.18632/oncotarget.8767. |
| 27853903 | Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders? | Biometals | 2017 Feb | Jodeiri Farshbaf M | doi: 10.1007/s10534-016-9981-x |
| 27015560 | mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer. | Oncotarget | 2016 May 3 | Chen Y | doi: 10.18632/oncotarget.8279. |
| 28741507 | mTOR Signaling Confers Resistance to Targeted Cancer Drugs. | Trends Cancer | 2016 Nov | Guri Y | doi: 10.1016/j.trecan.2016.10.006 |
| 29185784 | miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway. | DNA Cell Biol | 2018 Jan | Wang P | doi: 10.1089/dna.2017.3922 |
| 27462867 | Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis. | Oncotarget | 2016 Aug 30 | Zining J | doi: 10.18632/oncotarget.10805. |
| 27517315 | Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway. | Oncotarget | 2016 Sep 6 | Feng T | doi: 10.18632/oncotarget.11126. |
| 27974704 | MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. | Oncotarget | 2017 Jan 31 | Offermann A | doi: 10.18632/oncotarget.13860. |
| 27472392 | Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. | Oncotarget | 2016 Sep 6 | Henry RE | doi: 10.18632/oncotarget.10859. |
| 27863387 | Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling. | Oncotarget | 2016 Dec 27 | Dou N | doi: 10.18632/oncotarget.13354. |
| 28427795 | Reappraisal to the study of 4E-BP1 as an mTOR substrate - A normative critique. | Eur J Cell Biol | 2017 Jun | Batool A | doi: 10.1016/j.ejcb.2017.03.013 |
| 28569781 | Mitochondrial AKAP1 supports mTOR pathway and tumor growth. | Cell Death Dis | 2017 Jun 1 | Rinaldi L | doi: 10.1038/cddis.2017.241. |
| 28661070 | microRNA-145-3p inhibits non-small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway. | J Cell Biochem | 2018 Jan | Chen GM | doi: 10.1002/jcb.26252 |
| 28899863 | A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. | Cancer Discov | 2017 Nov | Rebecca VW | doi: 10.1158/2159-8290.CD-17-0741 |
| 29081412 | MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR. | Cancer Biomark | 2017 Dec 12 | Zhang S | doi: 10.3233/CBM-170620. |
| 29393469 | TRIM28 promotes cervical cancer growth through the mTOR signaling pathway. | Oncol Rep | 2018 Apr | Li F | doi: 10.3892/or.2018.6235 |
| 29484437 | miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. | Oncol Rep | 2018 Apr | Liu J | doi: 10.3892/or.2018.6268 |
| 28724614 | Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. | Genes Dev | 2017 Jun 15 | Audet-Walsh ?? | doi: 10.1101/gad.299958.117 |
| 29328491 | MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines MGC-803 and SGC-7901. | Oncol Rep | 2018 Mar | Fan H | doi: 10.3892/or.2018.6194 |
| 29488612 | Piperine depresses the migration progression via downregulating the Akt/mTOR/MMP9 signaling pathway in DU145 cells. | Mol Med Rep | 2018 May | Zeng Y | doi: 10.3892/mmr.2018.8653 |
| 29807226 | MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. | Biomed Pharmacother | 2018 Aug | Dai C | doi: 10.1016/j.biopha.2018.05.077 |
| 29086897 | Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. | Breast Cancer | 2018 Jul | Araki K | doi: 10.1007/s12282-017-0812-x |
| 29568966 | PPP2R2D, a regulatory subunit of protein phosphatase2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation. | Int J Oncol | 2018 Jun | Yu S | doi: 10.3892/ijo.2018.4329 |
| 29566977 | CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo. | Urol Oncol | 2018 Jun | Yan Y | doi: 10.1016/j.urolonc.2018.02.013 |
| 28332630 | PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4. | Sci Rep | 2017 Mar 23 | Salsman J | doi: 10.1038/srep45038. |
| 29862445 | Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer. | Appl Biochem Biotechnol | 2018 Dec | Razaviyan J | doi: 10.1007/s12010-018-2773-8 |
| 30272366 | Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer. | Oncol Rep | 2018 Dec | Guo H | doi: 10.3892/or.2018.6729 |
| 28484242 | Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. | Sci Rep | 2017 May 8 | Zhou X | doi: 10.1038/s41598-017-01729-w. |
| 30226616 | C16ceramide and sphingosine1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation. | Oncol Rep | 2018 Nov | Kim MH | doi: 10.3892/or.2018.6689 |
| 29449346 | Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway. | Biosci Rep | 2018 Apr 13 | Huang C | doi: 10.1042/BSR20171546 |
| 29133593 | Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women. | Mol Cancer Res | 2018 Feb | Sahoo SS | doi: 10.1158/1541-7786.MCR-17-0466 |
| 30419950 | LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. | J Exp Clin Cancer Res | 2018 Nov 12 | Feng M | doi: 10.1186/s13046-018-0947-4. |
| 29384225 | Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells. | J Cell Biochem | 2018 Jun | Gao X | doi: 10.1002/jcb.26742 |
| 29978580 | Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. | Int J Cancer | 2019 Jan 15 | Cheng L | doi: 10.1002/ijc.31656 |
| 30755508 | Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling. | MBio | 2019 Feb 12 | Bossler F | doi: 10.1128/mBio.02323-18. |
| 29408410 | The role of mTOR-mediated signaling in the regulation of cellular migration. | Immunol Lett | 2018 Apr | Holroyd AK | doi: 10.1016/j.imlet.2018.01.015 |
